Core Viewpoint - Hanbang Technology (688755.SH) reported a total operating revenue of 735 million yuan for the year 2025, representing a year-on-year growth of 6.40%, while the net profit attributable to the parent company was 59.59 million yuan, a decrease of 24.89% compared to the previous year [1] Group 1 - The company capitalized on opportunities in the biopharmaceutical equipment industry, continuously advancing market expansion and business layout, leading to a steady increase in revenue scale [1] - The decline in profitability was influenced by intensified market competition, fluctuations in downstream industry demand, and a decrease in the proportion of high-margin overseas revenue [1]

公司经营业绩变动的主要原因是：1)公司紧抓生物医药装备行业发展机遇，持续推进市场拓展与业务布 局，收入规模稳步提升;2)受市场竞争加剧、下游行业需求波动，叠加高毛利海外收入占比下降等因素 影响，公司盈利水平有所下滑。 汉邦科技(688755.SH)披露2025年度业绩快报，2025年度实现营业总收入7.35亿元，同比增长6.40%;归属 于母公司所有者的净利润5958.75万元，同比下降24.89%。 ...

Core Viewpoint - Hanbang Technology (688755.SH) reported a total operating revenue of 735 million yuan for the fiscal year 2025, representing a year-on-year growth of 6.40%. However, the net profit attributable to the parent company decreased by 24.89% to 59.59 million yuan, indicating challenges in profitability despite revenue growth [1]. Financial Performance - Total operating revenue for 2025 reached 735 million yuan, up 6.40% from the previous year [1] - Net profit attributable to the parent company was 59.59 million yuan, down 24.89% year-on-year [1] - Net profit excluding non-recurring gains and losses was 49.55 million yuan, a decline of 34.84% compared to the previous year [1] - Total assets at the end of 2025 amounted to 1.934 billion yuan, an increase of 45.96% from the beginning of the reporting period [1] - Equity attributable to the parent company reached 1.243 billion yuan, up 68.03% from the beginning of the reporting period [1] - Earnings per share attributable to the parent company increased by 26.02% to 14.12 yuan [1] Business Dynamics - The company capitalized on opportunities in the biopharmaceutical equipment industry, leading to steady revenue growth through market expansion and business layout [1] - Profitability faced challenges due to intensified market competition, fluctuations in downstream industry demand, and a decrease in the proportion of high-margin overseas revenue [1]

Financial Performance - The total operating revenue for 2025 was RMB 73,513.32 million, an increase of 6.40% compared to the previous year[4] - The net profit attributable to shareholders of the parent company was RMB 5,958.75 million, a decrease of 24.89% year-on-year[4] - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, was RMB 4,955.21 million, down 34.84% from the previous year[4] - Basic earnings per share decreased to RMB 0.76, a decline of 37.12% compared to the previous year[4] - The weighted average return on net assets was 5.79%, a decrease of 5.72 percentage points year-on-year[4] Assets and Equity - Total assets at the end of the reporting period were RMB 193,366.32 million, an increase of 45.96% from the beginning of the period[4] - Equity attributable to shareholders of the parent company increased to RMB 124,277.99 million, up 68.03% from the beginning of the period[4] - The company's total assets, equity, and share capital saw significant increases due to the completion of the IPO[8] Market Conditions - The decline in profitability was attributed to intensified market competition and fluctuations in downstream industry demand, along with a decrease in the proportion of high-margin overseas revenue[7] Initial Public Offering - The company completed its initial public offering of 22 million shares, raising a net amount of RMB 43,067.35 million after deducting issuance costs[8]

Core Viewpoint - Hanbang Technology announced a total operating revenue of 735 million yuan for the year 2025, representing a year-on-year growth of 6.40%. However, net profit decreased by 24.89% to 59.59 million yuan [1] Financial Performance - The total assets of the company at the end of 2025 reached 1.934 billion yuan, an increase of 45.96% compared to the beginning of the reporting period [1] - The equity attributable to the parent company was 1.243 billion yuan, reflecting a growth of 68.03% from the beginning of the reporting period [1] - The earnings per share attributable to the parent company increased to 14.12 yuan, marking a rise of 26.02% compared to the beginning of the reporting period [1]

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

Group 1 - The core point of the article is that Hanbang Technology announced a change in its signing registered accountants due to internal adjustments at Tianjian Accounting Firm [2] - The new signing registered accountants appointed are Zhu Junfeng and Yang Tianjiang, replacing Wu Hui [2]

江苏汉邦科技股份有限公司 证券代码：688755 证券简称：汉邦科技 公告编号：2026-003 关于变更签字注册会计师的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 经江苏汉邦科技股份有限公司（以下简称"公司"）第一届董事会第十八 次会议和公司2024年年度股东大会审议通过，同意聘任天健会计师事务所（特 殊普通合伙）（以下简称"天健会计师事务所"）担任公司2025年度财务报表 和内部控制审计机构。 近日，公司收到天健会计师事务所出具的《关于变更签字注册会计师的函》， 现将具体情况公告如下： 一、本次变更签字注册会计师的基本情况 天健会计师事务所作为公司2025年度财务报表和2025年末财务报告内部控 制审计机构，原委派吴慧和朱俊峰作为公司2025年度财务报表审计报告和2025 年末财务报告内部控制审计报告的签字注册会计师。由于天健会计师事务所内部 工作调整，现委派杨天将接替吴慧作为签字注册会计师。变更后的签字注册会计 师为朱俊峰和杨天将。 二、本次变更签字注册会计师的基本信息 1.人员信息 签字注册会计师：杨天将，2 ...

Group 1 - The core viewpoint of the news is that Hanbang Technology experienced a slight decline in stock price and notable changes in financing activities on January 19, with a net financing outflow of 292.90 thousand yuan [1] - On January 19, Hanbang Technology's financing buy amounted to 152.72 thousand yuan, while the financing balance reached 6,291.74 thousand yuan, accounting for 8.53% of the circulating market value [1] - The company specializes in providing separation and purification equipment, consumables, application technology services, and related technical solutions for the pharmaceutical and life sciences sectors, with revenue composition being 70.99% from small molecule drug separation and purification equipment, 22.94% from large molecule drug separation and purification equipment, and 6.07% from others [1] Group 2 - As of September 30, Hanbang Technology had 8,687 shareholders, a decrease of 7.31% from the previous period, while the average circulating shares per person increased by 7.89% [2] - For the period from January to September 2025, Hanbang Technology reported operating revenue of 506 million yuan, a year-on-year increase of 4.61%, but the net profit attributable to shareholders decreased by 17.27% to 37.02 million yuan [2] - Since its A-share listing, Hanbang Technology has distributed a total of 8.80 million yuan in dividends [2]

证券代码：688755 证券简称：汉邦科技 公告编号：2026-002 江苏汉邦科技股份有限公司 关于开立募集资金现金管理产品专用结算账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏汉邦科技股份有限公司（以下简称"公司"）于 2025 年 6 月 10 日召开 第一届董事会第十九次会议和第一届监事会第十一次会议，审议通过了《关于使 用部分暂时闲置募集资金进行现金管理的议案》，同意公司（含实施募投项目的 子公司，下同）在确保不影响公司正常经营、不影响募集资金投资计划正常进行 及确保募集资金安全的前提下，使用最高不超过人民币 39,800.00 万元（单日最 高余额，含本数）的暂时闲置募集资金进行现金管理，用于购买安全性高、流动 性好的保本型产品（包括但不限于保本型理财产品、定期存款、通知存款、大额 存单、协定存款、结构性存款、收益凭证等）。在上述额度范围内，资金可以滚 动使用，使用期限自公司董事会审议通过之日起 12 个月内有效。具体内容详见公 司于上海证券交易所网站（www.sse.com.cn）披露的《关 ...